Scientists in Spain have reported one of the most promising advances yet in the fight against pancreatic cancer, after a new study showed that an experimental triple-drug therapy completely eliminated aggressive pancreatic tumours in mice and prevented the disease from returning.
Pancreatic cancer remains one of the deadliest forms of cancer worldwide, largely because it is difficult to detect early and rapidly develops resistance to treatment. Survival rates have barely improved in decades, making any breakthrough in this field closely watched by doctors and researchers alike.
The study was led by researchers at Spain’s National Cancer Research Centre, who focused on pancreatic ductal adenocarcinoma — the most common and lethal form of the disease. Their approach targeted a well-known cancer driver called KRAS, a mutated oncogene present in the vast majority of pancreatic cancer cases.
Rather than blocking KRAS at a single point, which often allows tumours to adapt and survive, the scientists attacked the pathway at three critical stages simultaneously. The combination included an experimental KRAS inhibitor, a drug already approved for lung cancer treatment, and a protein-degrading compound designed to dismantle cancer-promoting signals at the molecular level.
The results were striking. Across three different animal models, pancreatic tumours regressed completely, with no significant toxicity observed during treatment. Even more notably, the cancers did not re-emerge after therapy stopped — a key hurdle that has undermined many previous experimental treatments.
Also Read: NHS bowel cancer screening update in England
Researchers believe the success lies in preventing cancer cells from developing escape routes. When only one part of the KRAS pathway is blocked, tumours often evolve resistance within weeks. By shutting down multiple survival mechanisms at once, the triple therapy appears to close off those escape options.
The findings were published in the peer-reviewed journal Proceedings of the National Academy of Sciences, adding credibility to what many experts see as a potentially transformative direction for future pancreatic cancer research.
Despite the excitement, the scientists were careful to urge caution. The treatment has not yet been tested in humans, and significant work remains before clinical trials can begin. Optimising drug doses, managing long-term safety, and ensuring effectiveness in patients will be complex challenges.
Still, cancer specialists say the study marks an important shift. Instead of searching for a single silver bullet, the research reinforces the idea that coordinated combination therapies may be the most realistic way to tackle cancers driven by powerful genetic mutations like KRAS.
For patients and families affected by pancreatic cancer, the breakthrough offers something that has long been in short supply: cautious but genuine hope. While a human cure remains distant, the study provides a clear roadmap toward treatments that could finally improve survival in one of medicine’s toughest battles.
